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ing needs and priorities changed from admission to discharge. 
Ten SCT patients completed both pre- and post-evaluation sur- 
veys. Results of this study highlight he need for greater attention 
to the psychosocial needs of transplant patients during the pre- 
and post-transplant period. Patients rated psychosocial issues very 
high on importance, but rated the teaching they received to help 
them deal with these concerns as relatively low. More attention 
should be devoted to the psychosocial needs and concerns of 
transplant patients throughout the entire SCT process. Learning 
about complimentary therapies that may be helpful in symptom 
management was not considered important to SCT patients, nor 
did they feel the teaching they r ceived helped them to under- 
stand complimentary therapies. Further study regarding the role 
of complimentary therapy in SCT and how patients are educated 
about these therapies i needed. Patients value knowing as much 
as possible about SCT, but commented that the large quantity of 
complex information limited their ability to retain the information 
they were given about transplantation. Both the timing and 
"dosage" of patient education about SCT requires additional 
study. Educating patients about SCT may be best accomplished in 
small doses with content hat varies across different phases 
throughout the transplant process. 
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SPERM QUALITY ACCORDING TO THE DISEASE AND TREATMENT 
PRE STEM CELL TRANSPLANTATION 
Choi, S/; Kim, t~7, Bok, j.1; Ira, J/; Kim, H. 2 1. St.3/IaJ 7 Hospital, 
Catholic HSCT, Seozd, Korea, South Korea; 2. Catholic University of 
Korea College of Ntr~'sing, Seoul, Korea, Somh Korea. 
Stem ceil transplantation is widely used method for the treat- 
ment of hematological malignancy and offers potential long- 
term survival. But cancer patient has defective sperm and low 
sperm counts a a consequence of the disease and its treatment. 
Irradiation and chemotherapy each compromise fertility by 
exerting cytotoxic effects on gametogenesis. The degree of 
gonadaI effect is governed by the therapeutic regimen(i.e., type, 
dose, schedule) and duration of treatment. This study was eval- 
uated the sperm quality before stem cell transplantation. 
Records of 50 patients with hematological malignance, who 
banked their sperm between Aug. 1998 and Aug. 2001, were 
reviewed. The acute leukemia group had undergone 
chemotherapy or radiation therapy before sperm banking. CML 
group had undergone conservative treatment. Some patients of 
SAA group had got ALG treatment. The sperm quality was 
examined by Volume, MSC(motile sperm count) and Motility. 
60% of all the patients were ol igospermic((20xl06/mL). 
Oligospermia occurred in 72% of the patients in Acute 
leukemia(n=13), 82% in the CML(n=14), and 20% in 
SAA(n=3). Total sperm volume did not differ significantly 
between the three groups. Compared with the other two 
leukemia group, patients in SAA group had higher 
MSC(p=0.0002) and Motility(p=0.0181). Sperm quality of SAA 
did not differ significantly between ALG treatment group and 
no treatment group. In conclusion, sperm quality of the 
leukemia patient who had got chemotherapy or radiation treat- 
ment was poor. The currently preferred practice for patients 
with cancer is to collect sperm before initiation of chemothera- 
py; therefore careful consideration of each individual's case 
must be the rule when determining how long therapy can be 
delayed without jeopardizing the patient's health. As cancer 
therapy may further impair sperm quality, patients hould be 
offered the chance to bank sperm before undergoing cancer 
therapy. 
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DEVELOPING A DATA SYSTEM TO MONITOR INFECTIOUS COMPLICA- 
TIONS AND MAKE CLINICAL DECISIONS BASED ON READILY ACCES- 
SIBLE DATA 
ffohm, A.A.; 3/largolese-~lalin, L. A&dt BMT Program, D1dee Uni- 
vers#y ~leclical Centel, Dztrham, NC. 
Susceptibility to infections continues to be a major source of 
morbidity and mortality during the course of hematopoetic cell 
transplantation (HCT). Advances in infection control including 
the use of growth factors, new antibiotics and strategies to prevent 
infections have improved survival rates and outcomes. However, 
resistant bacteria, latent viruses and fungal pathogens continue to 
challenge the success of HCT. As transplant programs investigate 
novel approaches to transplant including the use of reduced inten- 
sity transplants, utilizing alternative donor sources, and experi- 
menting with new agents to prevent or treat GVHD, the pattern 
and timing of pathogens may be altered. Transplant centers moni- 
tor and report infectious complications  a routine basis and 
institute measures to reduce the incidence of serious infections. 
Duke University Medical Center Adult HCT Program has devel- 
oped an integrated ata management system that allows the clini- 
cal staff to review infectious complications in relationship to a 
number of parameters. As the faculty continue to develop novel 
approaches to transplant, reat older patients, manipulate grafts, 
utilize new conditioning regimens and treat different underlying 
diseases, the emergence of opportunistic infections can be not 
only monitored but can also be linked to a number of variables. 
To ensure a comprehensive, authoritative base of information for 
ongoing analysis and review, Duke HCT has arranged for auto- 
mated data feeds from other programs uch as Microbiology, 
Infection Control, and Pulmonary Medicine. Further automation 
merges data from these external sources with Duke HCT own 
internal database. The results are then used to populate a number 
of analysis templates for quarterly review. Correlations and trends 
can be established for any or all of the variables listed above, and 
can be examined from both high level: program as whole, alloge- 
nieic, non-ablative cord blood or autologous transplants, and from 
lower level: by disease, protocol, gender, age, conditioning regi- 
men, and GVHD prophylaxis. Because the data gathering and 
presentation require little manual intervention, the results are 
readily available to clinical and administrative staff. With these 
data in hand, staff can more easily discern statistically significant 
trends and take remedial action quickly and efficiently. 
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ENSURING ACCURACY OF OUTPATIENT MEDICATION ADMINISTRA- 
TION FOR THE PEDIATRIC BONE MARROW TRANSPLANT PATIENT 
l,~an Stelle, J.LJ; Pasut, B/; Endrnd, L.Z; Sickel, A. I 1. The CT~ildrens 
Hospital, Denver, CO; 2. University of Colorado School of lVledicine, 
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The Bone Marrow Transplant (BMT) program at The Chil- 
dren's Hospital (TCH) in Denver, Colorado serves patients 
from the Rocky Mountain Area that includes nine states plus 
patients referred from other countries. The patients ages range 
from birth to the late twenties. The transplants are autologous 
and allogenic including matched related, unrelated, and cord 
blood. BMT patients are on between 6 and 20 medications as 
part of their supportive care in the post transplant time period. 
Nurses play a valuable role in educating patients and families of 
the importance and interactions of their medications, evaluat- 
ing compliance issues, and problem-solving roadblocks to suc- 
cessful medication administration. Home medication teaching 
is a multidiseiplinary process involving nurses, pharmacy and 
physicians. The process begins in-patient weeks prior to dis- 
charge and continues at each outpatient clinic visit. We will 
show several tools that help patients with safe medication 
administration. These are available in English and Spanish. 
Tools include: patient/parent medication list including side 
effects, clinic medication tracking list, patient/parent instruc- 
tion form (given with any medication change during the clinic 
visit), patient/parent medication checklist for home use, and 
medication calendars. In spite of this thorough medication 
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teaching process occurrences of non-compliance, lnisnnder- 
standing and miscommunication can still occur. We will also 
show different ways staff evaluates medication administration 
and compliance. 
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A REVIEW OF DONOR LYMPHOCYTE INFUSIONS USED IN NON-MYE- 
LOABLATIVE, T-CELL DEPLETED, ALLOGENEIC STEM CELL TRANS- 
PLANTS IN ADULTS 
Thompson, k/l., Rizzieri, D.; Cat~in, C.; BurlesoJz, J.; EreT1, 34.; k~lje- 
rich, D. Adult BoJTe Marrow TrmTsplm~t, Duke Universit), ~ledical 
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Allogeneic stem cell transplantation has been the cornerstone in 
long-term survival for many hematologic malignancies. Unfortu- 
nately, the myeloablative chemotherapy regimens can often be too 
rigorous for some patients. Non-myeloablative allogeneic stem 
cell transplantation is a relatively new concept in cancer treatment 
that can offer a potential benefit with less toxicity to patients who 
would not otherwise qualify for myeloablative treatment. The 
non-myeloablative preparative regimen is less toxic to the patient 
who can then benefit from the graft versus malignancy effect that 
the allogeneic stem cells can provide. Donor lymphocyte infilsions 
(DLI) are often given after t ansplantation to boost donor engraft- 
ment or to treat residual disease but can be associated with an 
increased risk of graft versus host disease. *When dosed correctly 
and at the appropriate time following the transplant, DLIs can be 
crucial in achieving 100% donor engraftment with minimal risk. 
This poster will review DLI dosages and associated toxicities in 37 
adult patients in a clinical trial using a non-myeloablative prepara- 
tive regimen followed by allogeneic transplant and post transplant 
DLIs. Developing a standard for dosing and transfusing DLls 
with minimal risk provides a unique challenge to our entire health 
care team and is an area that needs further esearch. 
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FUTURE FUNGAL FIGHTERS 
Rivera, Z.R. Blood aJz{l Marrow Tra*l~plmztation, MD Amlerso*7 
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Blood and Marrow Transplantation (BMT) patients are very 
susceptible to infections particularly of a fungal source. Invasive 
fimgal infections carry a high morbidity and mortality rate. Clini- 
cians are now taking a new approach to treat fungal infections due 
to recurrence, occurrence of resistant infections, aud increasing 
risk factors of transnfission of infection in susceptible hosts espe 
cially those patients with hematological disease or ou innnunosup- 
presive therapy. Most common fungal pathogens are of the Candi 
da species and Aspergillns pecies. Antifungal treamaent is given 
prior to and post BMT. Traditional treatment of choice to pre- 
vent fungal infection in BMT recipients is Fluconazole or Itra- 
conazole. In the treatment of fungal infection, the chosen thera- 
peutic option is Aurphotericin B or its lipid formation. The 
response to the current antifungal medications varies in patients. 
Monitoring of adverse reactions uch as chills, fever, and anaphy- 
laxis is also a priority; therefore premedications are necessary prior 
to the administration of Amphotericin B. Due to the effects these 
agents have on kidney and liver function, dosing of the medica- 
tions is critical. Despite the current treatments, resistant infections 
are beconaing a serious problem. In r~sponse to the problem of 
resistant fimgal infections: combination therapy or newer agents 
like Voriconazole and Caspofungin arc being used. Voriconazole 
and Caspofungin are less toxic on the kidneys and liver, premed- 
ications are not required, and thus better tolerated by BMT 
patients. A case study will be presented including prophylactic 
naanagelnent aswell as treatment of a BMT patient with fnngal 
infection. Continued research is being done to determine the best 
uses of these agents ahme or in combination therapy in order to 
better treat fungal infections in our BMT patients and decrease 
toxicities. 
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THE COMPLEXITY OF TRANSITIONING BLOOD AND MARROW 
PATIENTS FROM OUTPATIENT TO INPATIENT 
Cala'mm'a, J.M.; Stray, S.; Nemnam~, J.; Adorlletto, D.; Jolmstom P. 
~ID AmlersoTz Cm2cer Ce~zte~; Houstol~, TX. 
Transitioning the blood and marrow transplant patient from the 
outpatient clinic to the inpatient setting in a large comprehensive 
cancer center, perforuaing over 550 transplants a year, can be a 
challenging and complex process. During a collaborative review of 
this process, it was decided to focus on the admission procedure 
bem~een these areas to assure seamless commnnieation. The goal 
of this process was to provide a more consistent method of com- 
nrunicating information regarding the admission of a patient. The 
transplant team members identified the solution to be the creation 
of a designated admission folder. This fBlder is started for each 
patient being admitted, along with a checldist of required con- 
tents. The checldist is a document in which the outpatient staff 
verifies that the required contents are present in the folder. The 
checklist includes pre-transplant worknp, chemotherapy orders, 
height and weight, psychosocial ssessment by the social workers, 
copy of patient's blood and informed consent, patient's treatment 
plan and flowsheet including a complete disease history. The 
checklist is the key communication tool for staff and must be com- 
pleted before the patient leaves the clinic to be admitted. The 
checklist is completed on the day of admission, and contents of 
the folder reviewed by the transplant physician. The pharmacist 
also uses the iuformation in the folder to assist with writing the 
chemotherapy orders. The clinic nurse completes the checldist 
adding any comments or updates. The folder and checklist is then 
sent to the inpatient unit along with the patient naedicaI record. 
The beuefit o the inpatient unit is that all revelant docmnents are 
organized and placed in a designated folder, thereby, expiditing 
order transcription and the general admission process. At the 
present time, the folder acts as a transition for the electronic med 
ical records system, currently in the developmental stage. This 
folder and checklist creates a standard practice regarding the 
admission process in the Blood and Marrow Transplant clinic for 
the mulitdisiplinary team. A tool is being developed to audit the 
effectiveness of this new process. 
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TREATMENT PLANS FOR BLOOD AND MARROW TRANSPLANTATION 
PATIENTS; THE COMMUNICATION LINK 
Stray, &ft.; Willidms, P.A.; Crzls, E.; Graves, L.; Adornetto, D.L.; 
l,Valleet', J. B3dT CeJzter, UTMD Allde'rsom Houston7, TX. 
Transitioning patients through the Blood and Marrow Trans- 
plant (BMT) process requires seamless comnmnication amongst 
various healthcare team members and clinical areas. The treat- 
ment plan is a documentation tool that details the treatment pro- 
tocol and cell infusion for the transplant and serves as the commu- 
nication link between team uaembers in the inpatient and 
outpatient clinical areas. Initially, the treatment plan was imple- 
mented as a tool to communicate the patients transplant therapy 
to thc insurance company and the BMT clinical pharmacist. How- 
ever, it has evolved into the main treatment connnunication tool 
amongst the multidisciplinary teams. Through its evolution the 
need became apparent to standardize the form, establish accounta- 
bility for the team melnbers, and develop a policy and procedure. 
A nmltidisciplinary task tbrce was formed to discuss the current 
process, the purpose of the form, and the concerns related to 
patient safety in the administration of the correct therapy. This 
task force, evaluated the process flow, established policy and pro- 
cedure, standardized the form, and reverified the content of cur- 
rent treatment plans being utilized. Further development of this 
prqcess will include the accessibility of the treatment plans in a 
central repository of the BMT database. This repository will allow 
read and print capabilities to any team member and the ability of 
designated team members to monitor and maintain the repository. 
As a result of this process, treatment plans are utilized as the com- 
munication link to ensure the patients plan of care is clear, accu 
rate, documented, and approved by the attending physician. Also, 
this tool provides conmmnication to all caregivers in the inpatient 
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